ALS Breakthrough Research Fund

The Milken Institute LogoThe Milken Institute Center for Strategic Philanthropy and Tambourine have released an inaugural request for proposals (RFP) focused on understanding the underlying mechanisms of ALS. Letters of Intent are being accepted until June 21, 2023. Full proposals will be due September 1, 2023, Tambourine intends to award up to 10 ALS research grants in 2023, each providing up to US$300,000 in total funding per year for up to two years to support research projects led by independent investigators across the globe. Please download the RFP to learn more, and applicants are invited to apply via the Milken Institute’s application portal for this funding opportunity.

ALS – A Giving Smarter Guide

ALS, commonly known as Lou Gehrig’s disease or motor neurone disease (MND), is a cruel disease that has challenged patients, their families, and the medical community for generations. Although ALS is considered rare, its impact on individuals, families, and communities is devastating. The disabilities it causes make ALS the most expensive of neuromuscular disorders, with total costs estimated at more than $1 billion a year in the United States alone.

The ALS community desperately needs better ways to diagnose, measure, treat, and manage ALS. Still, progress has been constrained at all points by a lack of understanding of the disease’s basic biology and pathological mechanisms across the full diversity of people living with ALS. Strategic philanthropy can help overcome the barriers hindering progress in the ALS field, offering leadership and resources needed to understand and treat ALS for everyone.

This report by the Center for Strategic Philanthropy has identified a number of areas where an infusion of philanthropic capital could transform how we understand, manage, and treat ALS in all people living with the disease. There is an untapped opportunity for philanthropists to pull the levers that will drastically improve the quality of life and health outlook for all people living with ALS.


  • Each applicant organisation must be a non-profit academic or research institution, including domestic and non-US non-profit organisations and domestic non-US public/private academic universities or institutions of higher learning (including colleges, universities, medical schools, and other related academic research institutions); certain qualified governmental agencies with active biomedical research programs may also apply.
  • All proposed research projects must be led by one designated principal investigator (PI) who holds a PhD, MD, or related doctorate degree. PIs must be independent investigators.
    • New and / or early-stage investigators are encouraged to apply. New investigators are those who have not yet received substantial independent or federal funding for their independent research programs, while early-stage investigators are new investigators who are within 10 years of completing their terminal research degree, medical residency, or equivalent.
    • Multidisciplinary investigator collaborations are encouraged to apply. Collaborators should be identified as co-investigators and provide the materials described in the LOI guidance.
  • Institutions may submit multiple proposals, but a unique PI which lead each.
Full RFP Guidance



Visit funding web page

Translate »